Actively Recruiting
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-09-10
500
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are: * Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.
CONDITIONS
Official Title
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 18 and 79 years
- Received at least two cycles of neoadjuvant immunotherapy
- ECOG performance status score of 0
- Complete clinical information including imaging data available
You will not qualify if you...
- Diagnosed with or suspected active autoimmune diseases
- Presence of EGFR/ALK sensitive mutations
- Pregnant or breastfeeding women
- Previous anti-tumor therapies including chemotherapy or radiotherapy
- History of organ transplantation or hematopoietic stem cell transplantation
- Interstitial pneumonia, pulmonary fibrosis, or severe emphysema
- Uncontrolled diabetes mellitus
- Uncontrolled hypertension
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Actively Recruiting
Research Team
S
Shugeng Gao, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here